<DOC>
	<DOCNO>NCT01625000</DOCNO>
	<brief_summary>The objective study evaluate efficacy , safety , tolerability MP-214 relative placebo patient acute exacerbation schizophrenia .</brief_summary>
	<brief_title>Safety Efficacy MP-214 Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Written inform consent obtain patient initiation studyspecific procedures Patients diagnose schizophrenia accord diagnostic criterion Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion schizophrenia Patients normal physical examination , laboratory , vital sign , and/or electrocardiogram ( ECG ) Patients DSMIVTR diagnosis schizoaffective disorder , schizophreniform disorder , psychotic disorder schizophrenia , bipolar I II disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Acute Schizophrenia</keyword>
	<keyword>Mental Disorder</keyword>
	<keyword>Psychotropic Drugs</keyword>
	<keyword>Dopamine Agents</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>